证券代码：002365 证券简称：永安药业 公告编号：2025-35 潜江永安药业股份有限公司 关于股票交易异常波动暨风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易价格于 2025 年 5 月 21 日、2025 年 5 月 22 日连续 两个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳证券交易所的有关 规定，属于股票交易异常波动的情况。公司股价短期涨幅较大，敬请广大投资者 理性投资，注意投资风险。 2、截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市 盈率为 80.30，滚动市盈率为 172.69；公司所属中上协行业分类"医药制造业" 的静态市盈率为 28.46，滚动市盈率为 28.01。公司静态市盈率、滚动市盈率高 于公司所属中上协行业分类"医药制造业"水平。2025 年一季度，公司处于亏 损状态。公司特别提醒投资 ...

Group 1 - The graphite electrode sector experienced a decline of 2.91%, ranking among the top losers in the concept sector as of the market close on May 22 [1][2] - Within the graphite electrode sector, major companies such as Xiangfenghua, Zhongke Electric, and Daoshi Technology saw significant declines in their stock prices [1][2] - Conversely, two companies, Yong'an Pharmaceutical and Guomin Technology, reported stock price increases of 9.98% and 0.21%, respectively [1][2] Group 2 - The graphite electrode sector faced a net outflow of 300 million yuan from main funds, with 17 stocks experiencing net outflows, and 9 stocks seeing outflows exceeding 10 million yuan [2] - Baosteel Co. led the net outflow with 87.84 million yuan, followed by Daoshi Technology and Zhongke Electric with outflows of 70.63 million yuan and 68.48 million yuan, respectively [2] - In contrast, Yong'an Pharmaceutical, Guomin Technology, and Yicheng New Energy were the top gainers in net inflow, attracting 49.32 million yuan, 23.62 million yuan, and 1.79 million yuan, respectively [2][3]

永安药业午后涨停，走出两连板。 ...

Group 1 - The graphite electrode concept sector increased by 2.57%, ranking first among concept sectors, with 17 stocks rising, including Ningxin New Materials which hit a 30% limit up, and Yong'an Pharmaceutical also hitting the limit up, while Dongfang Carbon, Xiangfenghua, and Better Ray saw increases of 11.54%, 5.78%, and 3.30% respectively [1][2] - The sector attracted a net inflow of 263 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan, led by Yong'an Pharmaceutical with a net inflow of 260 million yuan [2][3] - The top three stocks by net inflow ratio were Yong'an Pharmaceutical at 20.71%, China Baoan at 17.14%, and Xiangfenghua at 10.64% [3][4] Group 2 - The top performing stocks in the graphite electrode concept included Yong'an Pharmaceutical, with a daily increase of 10.00% and a turnover rate of 30.78%, followed by Daoshi Technology and Zhongke Electric with increases of 2.77% and 3.28% respectively [3][4] - The stocks with the largest declines included Fuan Co., which fell by 2.92%, and Guomin Technology and Shanshan Co., which decreased by 1.95% and 1.56% respectively [1][4] - The overall market performance showed a mixed trend, with several sectors experiencing declines, while the graphite electrode sector stood out with significant gains [2][3]

Core Viewpoint - Yong'an Pharmaceutical has seen a significant stock price increase, reaching a new high of 15.41 yuan per share, attributed to rising export prices of taurine products and strong market interest in the taurine industry [1][4]. Company Performance - As of May 19, Yong'an Pharmaceutical's stock price increased by 9.99%, with a net inflow of 182 million yuan in main funds on that day [1][2]. - Since April 1, the company's stock has risen by 86.11%, with three limit-up days in four trading sessions following a limit-up on May 14 [4]. - The company reported a net profit of 61.76 million yuan for 2024, marking a turnaround from losses [5]. Industry Context - Yong'an Pharmaceutical is a leading player in the taurine industry, holding over 50% of the global market share with an annual production capacity of 58,000 tons [4]. - The export prices for pharmaceutical-grade taurine reached 8.9 USD per kilogram and food-grade taurine at 6.89 USD per kilogram in April, indicating a significant price increase [4]. - The market has shown increased interest in the taurine supply chain, with related sectors such as health products and pet economy performing well, supporting Yong'an Pharmaceutical's stock price rise [5]. Management and Governance - The company is actively engaged in the research, production, and sales of functional foods and health products through its subsidiary, Yong'an Kangjian Pharmaceutical [5]. - There is ongoing market attention regarding the investigation of the company's chairman, which may impact operational decisions and market confidence [6].

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

Mergers and Acquisitions - Multiple companies are experiencing stock price increases due to merger and acquisition activities, with notable gains including Zongyi Co. at 10.10% and Daqimo at 10.06% [2][3] - New entrants in the market such as Binhai Energy and Jinhongshun also saw significant increases of 10.00% and 9.98% respectively, attributed to similar merger activities [2] - The trend continues with companies like Huayuan Real Estate and Hunan Development achieving first board listings with gains of 9.94% and 9.97% [3] Shipping and Ports - Following the implementation of tariff adjustments between China and the US, there has been a surge in container bookings from China to the US, positively impacting shipping and port stocks [4] - Nanjing Port, Ningbo Shipping, and Lianyungang have all recorded five consecutive days of price increases, with gains of 9.97%, 10.04%, and 10.07% respectively [4][6] Robotics - The robotics sector is gaining attention, with Nvidia's CEO indicating that all mobile devices will become robots, potentially revolutionizing the industrial sector [7] - Companies like Zhongchao Holdings and Xinlong Health have seen stock increases of 10.13% and 10.01% respectively, driven by advancements in robotics [8] Chemical Products - Recent price hikes in chemical products such as dibutyl phthalate and hydroxyl esters have drawn market attention, benefiting companies like Zhongyida and Youfu Co. with stock increases of 9.99% and 10.04% [10][11] Food and Beverage - The release of new regulations by the Ministry of Commerce and the National Development and Reform Commission is expected to boost the food and beverage sector, with stocks like Jiaoda Angli and Baihe Co. seeing gains of 10.00% and 10.01% [12][15] Military and Aerospace - The debut of the "Jiutian" drone at the 15th China Airshow is anticipated to enhance the military sector, with companies like Chengfei Integration and Lijun Co. achieving stock increases of 10.00% and 10.02% [16][19] Nuclear Power - The announcement of procurement projects by China Fusion Energy Co. is expected to stimulate the nuclear power sector, benefiting companies like Wangzi New Materials and Baili Electric with stock increases of 9.99% and 9.92% [16][17] Venture Capital - Recent regulatory changes encouraging private equity participation in mergers and acquisitions are positively impacting venture capital stocks, with companies like Jiuding Investment and Electronic City seeing gains of 10.01% and 9.90% [19] Pet Economy - The pet economy is projected to grow significantly, with companies like Yuande Pet and Tianyuan Pet achieving stock increases of 9.98% and 20.00% [20][21] Carbon Fiber - Price increases in carbon fiber products have been reported, benefiting companies like Jilin Chemical Fiber with a stock increase of 10.04% [22][23] Smart Driving - The Ministry of Industry and Information Technology's push for mandatory standards in smart connected vehicles is expected to drive growth in the automotive sector, with companies like Wan'an Technology and Luchang Technology seeing stock increases of 10.00% [26][27] Rare Earth Permanent Magnets - Tightening supply of rare earth materials due to export controls has led to price increases, benefiting companies like Huayang New Materials and Jiuwu High-Tech with stock increases of 10.10% and 20.02% [28][29] Huawei Harmony - Huawei's upcoming product launch is expected to positively impact related stocks, with companies like Dongfang Zhongke and Dahua Intelligent seeing stock increases of 10.01% and 9.94% [30]

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical (002365) has experienced a significant stock price increase of 9.99% as of May 19, 2025, closing at 15.41 yuan, with a trading volume of 507,300 hands and a transaction amount of 767 million yuan [1] - The company reported a total operating revenue of 171 million yuan for Q1 2025, representing a year-on-year decrease of 12.96%, and a net profit attributable to shareholders of 4.37 million yuan, down 115.23% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 5.289 and a quick ratio of 4.876, while the debt-to-asset ratio stands at 10.45% [1] Group 2 - Yong'an Pharmaceutical has made investments in 8 external companies and participated in 20 bidding projects, indicating active engagement in business expansion [2] - The company holds 3 trademark registrations and 39 patents, showcasing its commitment to intellectual property development [2] - Yong'an Pharmaceutical has obtained 278 administrative licenses, reflecting its compliance and operational capabilities within the industry [2]

Group 1 - The pet economy concept rose by 1.98%, ranking third among concept sectors, with 54 stocks increasing in value, including major gainers like Meino Biological and Jieya Co., which hit the 20% limit up [1][2] - Notable stocks with significant increases include Xianle Health, Huisheng Biological, and Yiyuan Magic Yam, which rose by 13.41%, 10.50%, and 9.10% respectively [1] - The leading decliners in the sector were Zhiou Technology, Qingmu Technology, and Yingstone Network, which fell by 4.64%, 4.42%, and 2.73% respectively [1] Group 2 - The pet economy sector saw a net inflow of 236 million yuan, with 48 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top stock for net inflow was Yong'an Pharmaceutical, with a net inflow of 68.36 million yuan, followed by Jieya Co., Ruoyuchen, and Meino Biological with net inflows of 48.24 million yuan, 46.14 million yuan, and 45.47 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Jieya Co., Jiabiyou, and Meino Biological led with net inflow rates of 27.98%, 13.31%, and 11.04% respectively [3] - The pet economy sector's inflow ranking included stocks like Yong'an Pharmaceutical, Jieya Co., Ruoyuchen, and Meino Biological, all showing strong performance in terms of trading volume and turnover rates [3][4]

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase exceeding 20% over two consecutive trading days on May 14 and May 15, 2025 [1][2] - The board of directors confirmed that there are no undisclosed significant matters related to the company, and the recent operational situation remains normal without major changes in the internal and external business environment [2] - The company has not identified any undisclosed information that could significantly impact its stock price, and previous disclosures do not require correction or supplementation [2][3] Group 2 - The company is closely monitoring the situation regarding its actual controller and chairman being detained, and will fulfill its information disclosure obligations as required [1][2] - The board of directors emphasized that there are no violations of fair information disclosure, and all information should be verified through designated media [2]